Top

Published in:

01-06-2014 | Original Paper

Clinicopathologic Characteristics of Brain Tumors are Associated with the Presence and Patterns of TP53 Mutations: Evidence from the IARC TP53 Database

Author: Lyubov E. Salnikova

Published in: NeuroMolecular Medicine | Issue 2/2014

Abstract

Biological diversity in the development and progression of brain tumors may be based on the consequences of the nature of the TP53 mutation in the cancer sample. This study was designed to estimate the possible impact of the presence and spectrum of TP53 mutations on clinical variability of brain tumors using the IARC TP53 Database (R17). Somatic and germline mutation patterns differ in brain tumor carriers. The most frequent mutation in sporadic brain tumors is mutation R273C, which is relatively rare in grade 4 tumors compared with lower-grade tumors (p = 1.2 × 10⁻⁵, OR 0.43, 95 % CI 0.29–0.63). Mutations at all hot spots, DNA contact mutations, and mutations in the conserved regions of the TP53 gene are also more common in grade 1–3 tumors than in grade 4 tumors. The frequencies of missense mutations at hotspot codons and DNA contact mutations gradually decrease in all three age groups studied, indicating the role of these mutations in early-onset tumors. The role of TP53 somatic mutations in the development of brain tumors has been elucidated in the individual-participant meta-analysis that provided, for the first time, strong evidence that mean age at the onset of sporadic brain tumor is significantly lower in patients with mutated compared with wild-type TP53 in all groups stratified by tumor grade. The presence and patterns of TP53 mutations are associated mainly with the age at the onset and with the development of less malignant brain tumors. Malignant degeneration of brain tumors may depend on other genetic determinants.

Available only for authorised users

Abramson, J. H. (2011). WINPEPI updated: Computer programs for epidemiologists, and their teaching potential. Epidemiologic Perspectives and Innovations, 8, 1. doi:10.1186/1742-5573-8-1.PubMedCentralPubMedCrossRef

Bäcklund, L. M., Nilsson, B. R., Liu, L., Ichimura, K., & Collins, V. P. (2005). Mutations in Rb1 pathway-related genes are associated with poor prognosis in anaplastic astrocytomas. British Journal of Cancer, 93, 124–130. doi:10.1038/sj.bjc.6602661.PubMedCentralPubMedCrossRef

Batchelor, T. T., Betensky, R. A., Esposito, J. M., Pham, L. D., Dorfman, M. V., Piscatelli, N., et al. (2004). Age-dependent prognostic effects of genetic alterations in glioblastoma. Clinical Cancer Research, 10, 228–233.PubMedCrossRef

Berg, M., Danielsen, S. A., Ahlquist, T., Merok, M. A., Ågesen, T. H., Vatn, M. H., et al. (2010). DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PLoS ONE, 5(11), e13978. doi:10.1371/journal.pone.0013978.PubMedCentralPubMedCrossRef

Bleeker, F. E., Molenaar, R. J., & Leenstra, S. (2012). Recent advances in the molecular understanding of glioblastoma. Journal of Neuro-oncology, 108, 11–27. doi:10.1007/s11060-011-0793-0.PubMedCentralPubMedCrossRef

Bougeard, G., Sesboüé, R., Baert-Desurmont, S., Vasseur, S., Martin, C., Tinat, J., et al. (2008). Molecular basis of the Li–Fraumeni syndrome: An update from the French LFS families. Journal of Medical Genetics, 45, 535–538. doi:10.1136/jmg.2008.057570.PubMedCrossRef

Chen, P., Aldape, K., Wiencke, J. K., Kelsey, K. T., Miike, R., Davis, R. L., et al. (2001). Ethnicity delineates different genetic pathways in malignant glioma. Cancer Research, 61, 3949–3954.PubMed

Chen, Y. J., Hakin-Smith, V., Teo, M., Xinarianos, G. E., Jellinek, D. A., Carroll, T., et al. (2006). Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Research, 66, 6473–6476. doi:10.1158/0008-5472.CAN-06-0910.PubMedCrossRef

Chung, R., Whaley, J., Kley, N., Anderson, K., Louis, D., Menon, A., et al. (1991). TP53 gene mutations and 17p deletions in human astrocytomas. Genes, Chromosomes and Cancer, 3, 323–331. doi:10.1002/gcc.2870030502.PubMedCrossRef

Dearth, L. R., Qian, H., Wang, T., Baroni, T. E., Zeng, J., Chen, S. W., et al. (2007). Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis, 28, 289–298. doi:10.1093/carcin/bgl132.PubMedCrossRef

Duan, W., Gao, L., Wu, X., Hade, E. M., Gao, J. X., Ding, H., et al. (2009). Expression of a mutant p53 results in an age-related demographic shift in spontaneous lung tumor formation in transgenic mice. PLoS ONE, 4(5), e5563. doi:10.1371/journal.pone.0005563.PubMedCentralPubMedCrossRef

Felsberg, J., Rapp, M., Loeser, S., Fimmers, R., Stummer, W., Goeppert, M., et al. (2009). Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clinical Cancer Research, 15, 6683–6693. doi:10.1158/1078-0432.CCR-08-2801.PubMedCrossRef

Fernández-Cuesta, L., Oakman, C., Falagan-Lotsch, P., Smoth, K. S., Quinaux, E., Buyse, M., et al. (2012). Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: Results from the BIG 02-98 phase III trial. Breast Cancer Research, 14(3), R70. doi:10.1186/bcr3179.PubMedCentralPubMedCrossRef

Forrester, K., Lupold, S. E., Ott, V. L., Chay, C. H., Band, V., Wang, X. W., et al. (1995). Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene, 10, 2103–2111.PubMed

Hainaut, P., Olivier, M., & Wiman, K. (Eds.). (2013). p53 in the clinics. New York: Springer.

Ishii, N., Tada, M., Hamou, M. F., Janzer, R. C., Meagher-Villemure, K., Wiestler, O. D., et al. (1999). Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor. Oncogene, 18, 5870–5878.PubMedCrossRef

Jha, P., Suri, V., Singh, G., Jha, P., Purkait, S., Pathak, P., et al. (2011). Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults. Diagnostic Molecular Pathology, 20, 225–232. doi:10.1097/PDM.0b013e31821c30bc.PubMedCrossRef

Kato, S., Han, S. Y., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R., et al. (2003). Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proceedings of the National Academy of Sciences of the United States of America, 100, 8424–8429. doi:10.1073/pnas.1431692100.PubMedCentralPubMedCrossRef

Kim, Y. H., Nobusawa, S., Mittelbronn, M., Paulus, W., Brokinkel, B., Keyvani, K., et al. (2010). Molecular classification of low-grade diffuse gliomas. American Journal of Pathology, 177, 2708–2714. doi:10.2353/ajpath.2010.100680.PubMedCentralPubMedCrossRef

Köbel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., et al. (2008). Ovarian carcinoma subtypes are different diseases: Implications for biomarker studies. PLoS Med, 5(12), e232. 10.1371/journal.pmed.0050232.PubMedCentralPubMedCrossRef

Kösel, S., Scheithauer, B. W., & Graeber, M. B. (2001). Genotype-phenotype correlation in gemistocytic astrocytomas. Neurosurgery, 48, 187–193.PubMedCrossRef

Kraus, J. A., Wenghoefer, M., Glesmann, N., Mohr, S., Beck, M., Schmidt, M. C., et al. (2001). TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme. Journal of Neuro-oncology, 52, 263–272.PubMedCrossRef

Kuilman, T., Michaloglou, C., Mooi, W. J., & Peeper, D. S. (2010). The essence of senescence. Genes & Development, 24, 2463–2479. doi:10.1101/gad.1971610.CrossRef

Leiserson, M. D., Blokh, D., Sharan, R., & Raphael, B. J. (2013). Simultaneous identification of multiple driver pathways in cancer. PLoS Computational Biology, 9(5), e1003054. doi:10.1371/journal.pcbi.1003054.PubMedCentralPubMedCrossRef

Louis, D. N., von Deimling, A., Chung, R. Y., Rubio, M. P., Whaley, J. M., Eibl, R. H., et al. (1993). Comparative study of p53 gene and protein alterations in human astrocytic tumors. Journal of Neuropathology and Experimental Neurology, 52, 31–38.PubMedCrossRef

McLendon, R. E., Herndon, J. E., I. I., West, B., Reardon, D., Wiltshire, R., Rasheed, B. K., et al. (2005). Survival analysis of presumptive prognostic markers among oligodendrogliomas. Cancer, 104, 1693–1699. doi:10.1002/cncr.21362.PubMedCrossRef

Mendrysa, S. M., Ghassemifar, S., & Malek, R. (2011). p53 in the CNS: Perspectives on development, stem cells, and cancer. Genes Cancer, 2, 431–442. doi:10.1177/1947601911409736.PubMedCentralPubMedCrossRef

Mitchell, G., Ballinger, M. L., Wong, S., Hewitt, C., James, P., Young, M. A., et al. (2013). High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohort. PLoS ONE, 8(7), e69026. 10.1371/journal.pone.0069026.PubMedCentralPubMedCrossRef

Mukhopadhyay, T., & Roth, J. A. (1993). A codon 248 p53 mutation retains tumor suppressor function as shown by enhancement of tumor growth by antisense p53. Cancer Research, 53, 4362–4366.PubMed

Muller, P. A., & Vousden, K. H. (2013). p53 mutations in cancer. Nature Cell Biology, 15, 2–8. doi:10.1038/ncb2641.PubMedCrossRef

Ognjanovic, S., Olivier, M., Bergemann, T. L., & Hainaut, P. (2012). Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 Database. Cancer, 118, 1387–1396. doi:10.1002/cncr.26390.PubMedCrossRef

Ohgaki, H., & Kleihues, P. (2007). Genetic pathways to primary and secondary glioblastoma. American Journal of Pathology, 170, 1445–1453. doi:10.2353/ajpath.2007.070011.PubMedCentralPubMedCrossRef

Ohgaki, H., & Kleihues, P. (2011). Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathology, 28, 177–183. doi:10.1007/s10014-011-0029-1.PubMedCrossRef

Olar, A., & Aldape, K. D. (2012). Biomarkers classification and therapeutic decision-making for malignant gliomas. Current Treatment Options in Oncology, 13, 417–436. doi:10.1007/s11864-012-0210-8.PubMedCrossRef

Olivier, M. (2013). TP53 somatic mutations: Prognostic and predictive value in human cancers. In P. Hainaut, M. Olivier, & K. G. Wiman (Eds.), p53 in the clinics (pp. 127–146). New York: Springer.CrossRef

Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002). The IARC TP53 Database: New online mutation analysis and recommendations to users. Human Mutation, 19, 607–614. doi:10.1002/humu.10081.PubMedCrossRef

Olivier, M., Goldgar, D. E., Sodha, N., Ohgaki, H., Kleihues, P., Hainaut, P., et al. (2003). Li-Fraumeni and related syndromes: Correlation between tumor type, family structure, and TP53 genotype. Cancer Research, 63, 6643–6650.PubMed

Olivier, M., Langerød, A., Carrieri, P., Bergh, J., Klaar, S., Eyfjord, J., et al. (2006). The clinical value of somatic TP53 gene mutations in 1, 794 patients with breast cancer. Clinical Cancer Research, 12, 1157–1167. doi:10.1158/1078-0432.CCR-05-1029.PubMedCrossRef

Olivier, M., Petitjean, A., Marcel, V., Pétré, A., Mounawar, M., Plymoth, A., et al. (2009). Recent advances in p53 research: An interdisciplinary perspective. Cancer Gene Therapy, 16, 1–12. doi:10.1038/cgt.2008.69.PubMedCrossRef

Olivier, M., Hollstein, M., & Hainaut, P. (2010). TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harbor Perspectives in Biology, 2(1), a001008. doi:10.1101/cshperspect.a001008.PubMedCentralPubMedCrossRef

Oren, M., & Rotter, V. (2010). Mutant p53 gain-of-function in cancer. Cold Spring Harbor Perspectives in Biology, 2(2), a001107. doi:10.1101/cshperspect.a001107.PubMedCentralPubMedCrossRef

O’Shea, D., O’Riain, C., Taylor, C., Waters, R., Carlotti, E., Macdougall, F., et al. (2008). The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood, 112, 3126–3129. doi:10.1182/blood-2008-05-154013.PubMedCentralPubMedCrossRef

Peraud, A., Kreth, F. W., Wiestler, O. D., Kleihues, P., & Reulen, H. J. (2002). Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clinical Cancer Research, 8, 1117–1124.PubMed

Petitjean, A., Achatz, M. I., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007a). P53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene, 26, 2157–2165. 10.1038/sj.onc.1210302.PubMedCrossRef

Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., et al. (2007b). Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 Database. Human Mutation, 28, 622–629. doi:10.1002/humu.20495.PubMedCrossRef

Pollack, I. F., Finkelstein, S. D., Woods, J., Burnham, J., Holmes, E. J., Hamilton, R. L., et al. (2002). Expression of p53 and prognosis in children with malignant gliomas. New England Journal of Medicine, 346, 420–427. doi:10.1056/NEJMoa012224.PubMedCrossRef

Powell, B., Soong, R., Iacopetta, B., Seshadri, R., & Smith, D. R. (2000). Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clinical Cancer Research, 6, 443–451.PubMed

Rasheed, B. K., McLendon, R. E., Herndon, J. E., Friedman, H. S., Friedman, A. H., Bigner, D. D., et al. (1994). Alterations of the TP53 gene in human gliomas. Cancer Research, 54, 1324–1330.PubMed

Rasheed, A., Herndon, J. E., Stenzel, T. T., Raetz, J. G., Kendelhardt, J., & Friedman, H. S. (2002). Molecular markers of prognosis in astrocytic tumors. Cancer, 94, 2688–2697. doi:10.1002/cncr.10544.PubMedCrossRef

Reifenberger, J., Ring, G. U., Gies, U., Cobbers, L., Oberstrass, J., An, H. X., et al. (1996). Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. Journal of Neuropathology and Experimental Neurology, 55, 822–831.PubMedCrossRef

Resnick, M. A., & Inga, A. (2003). Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proceedings of the National Academy of Sciences of the United States of America, 100, 9934–9939. doi:10.1073/pnas.1633803100.PubMedCentralPubMedCrossRef

Rücker, F. G., Schlenk, R. F., Bullinger, L., Kayser, S., Teleanu, V., Kett, H., et al. (2012). TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood, 119, 2114–2121. doi:10.1182/blood-2011-08-375758.PubMedCrossRef

Schmidt, M. C., Antweiler, S., Urban, N., Mueller, W., Kuklik, A., Meyer-Puttlitz, B., et al. (2002). Impact of genotype and morphology on the prognosis of glioblastoma. Journal of Neuropathology and Experimental Neurology, 61, 321–328.PubMed

Shiraishi, S., Tada, K., Nakamura, H., Makino, K., Kochi, M., Saya, H., et al. (2002). Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer, 95, 249–257. doi:10.1002/cncr.10677.PubMedCrossRef

Smith, J. S., Tachibana, I., Passe, S. M., Huntley, B. K., Borell, T. J., Iturria, N., et al. (2001). PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. Journal of the National Cancer Institute, 93, 1246–1256. doi:10.1093/jnci/93.16.1246.PubMedCrossRef

Soussi, T. (2007). p53 alterations in human cancer: More questions than answers. Oncogene, 26, 2145–2156. doi:10.1038/sj.onc.1210280.PubMedCrossRef

Stander, M., Peraud, A., Leroch, B., & Kreth, F. W. (2004). Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: A longterm analysis. Cancer, 101, 1028–1035. doi:10.1002/cncr.20432.PubMedCrossRef

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2012 Sub (1973-2010 varying)—Linked To County Attributes—Total U.S., 1969-2011 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission.

Thon, N., Eigenbrod, S., Kreth, S., Lutz, J., Tonn, J. C., Kretzschmar, H., et al. (2012). IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer, 118, 452–460. doi:10.1002/cncr.26298.PubMedCrossRef

Vaupel, P. (2010). Metabolic microenvironment of tumor cells: A key factor in malignant progression. Experimental Oncology, 32, 125–127.PubMed

Walerych, D., Napoli, M., Collavin, L., & Del Sal, G. (2012). The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis, 33, 2007–2017. doi:10.1093/carcin/bgs232.PubMedCentralPubMedCrossRef

Walker, C., du Plessis, D. G., Joyce, K. A., Fildes, D., Gee, A., Haylock, B., et al. (2005). Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Annals of Neurology, 57, 855–865. doi:10.1002/ana.20496.PubMedCrossRef

Watanabe, T., Katayama, Y., Yoshino, A., Komine, C., & Yokoyama, T. (2003). Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course. Clinical Cancer Research, 9, 4884–4890.PubMed

Wiestler, B., Claus, R., Hartlieb, S. A., Schliesser, M. G., Weiss, E. K., Hielscher, T., et al. (2013). Malignant astrocytomas of elderly patients lack favorable molecular markers: An analysis of the NOA-08 study collective. Neuro-oncology, 15, 1017–1026. doi:10.1093/neuonc/not043.PubMedCrossRef

Wiman, K. G. (2010). Pharmacological reactivation of mutant p53: From protein structure to the cancer patient. Oncogene, 29, 4245–4252. doi:10.1038/onc.2010.188.PubMedCrossRef

Wunder, J. S., Gokgoz, N., Parkes, R., Bull, S. B., Eskandarian, S., & Davis, A. M. (2005). TP53 mutations and outcome in osteosarcoma: A prospective, multicenter study. Journal of Clinical Oncology, 23, 1483–1490. doi:10.1200/JCO.2005.04.074.PubMedCrossRef

Yu, X., Vazquez, A., Levine, A. J., & Carpizo, D. R. (2012). Allele-specific p53 mutant reactivation. Cancer Cell, 21, 614–625. doi:10.1016/j.ccr.2012.03.042.PubMedCentralPubMedCrossRef

Zerdoumi, Y., Aury-Landas, J., Bonaïti-Pellié, C., Derambure, C., Sesboüé, R., & Renaux-Petel, M. (2013). Drastic effect of germline TP53 missense mutations in Li–Fraumeni patients. Human Mutation, 34, 453–461. doi:10.1002/humu.22254.PubMedCrossRef

Zou, P., Xu, H., Chen, P., Yan, Q., Zhao, L., Zhao, P., et al. (2013). IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: A meta-analysis. PLoS ONE, 8(7), e68782. doi:10.1371/journal.pone.0068782.PubMedCentralPubMedCrossRef

Title: Clinicopathologic Characteristics of Brain Tumors are Associated with the Presence and Patterns of TP53 Mutations: Evidence from the IARC TP53 Database
Author: Lyubov E. Salnikova
Publication date: 01-06-2014
Publisher: Springer US
Published in: NeuroMolecular Medicine / Issue 2/2014
Print ISSN: 1535-1084
Electronic ISSN: 1559-1174
DOI: https://doi.org/10.1007/s12017-014-8290-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clinicopathologic Characteristics of Brain Tumors are Associated with the Presence and Patterns of TP53 Mutations: Evidence from the IARC TP53 Database

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

C-terminus of Human BKca Channel Alpha Subunit Enhances the Permeability of the Brain Endothelial Cells by Interacting with Caveolin-1 and Triggering Caveolin-1 Intracellular Trafficking

Tellurium Compound AS101 Ameliorates Experimental Autoimmune Encephalomyelitis by VLA-4 Inhibition and Suppression of Monocyte and T Cell Infiltration into the CNS

Blockade of Nav1.8 Currents in Nociceptive Trigeminal Neurons Contributes to Anti-trigeminovascular Nociceptive Effect of Amitriptyline

The SIRT2 Polymorphism rs10410544 and Risk of Alzheimer’s Disease: A Meta-analysis

Blocking NMDA Receptors Delays Death in Rats with Acute Liver Failure by Dual Protective Mechanisms in Kidney and Brain

Deciphering the Roles of Trehalose and Hsp104 in the Inhibition of Aggregation of Mutant Huntingtin in a Yeast Model of Huntington’s Disease